JP2008524218A5 - - Google Patents

Download PDF

Info

Publication number
JP2008524218A5
JP2008524218A5 JP2007546709A JP2007546709A JP2008524218A5 JP 2008524218 A5 JP2008524218 A5 JP 2008524218A5 JP 2007546709 A JP2007546709 A JP 2007546709A JP 2007546709 A JP2007546709 A JP 2007546709A JP 2008524218 A5 JP2008524218 A5 JP 2008524218A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
compound
hodgkin lymphoma
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007546709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008524218A (ja
JP5022911B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/043125 external-priority patent/WO2006065525A1/en
Publication of JP2008524218A publication Critical patent/JP2008524218A/ja
Publication of JP2008524218A5 publication Critical patent/JP2008524218A5/ja
Application granted granted Critical
Publication of JP5022911B2 publication Critical patent/JP5022911B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2007546709A 2004-12-17 2005-11-30 ゲムシタビンのアミドプロドラック、組成物、及びそれらの使用 Expired - Fee Related JP5022911B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63742204P 2004-12-17 2004-12-17
US60/637,422 2004-12-17
PCT/US2005/043125 WO2006065525A1 (en) 2004-12-17 2005-11-30 Amide prodrug of gemcitabine, compositions and use thereof

Publications (3)

Publication Number Publication Date
JP2008524218A JP2008524218A (ja) 2008-07-10
JP2008524218A5 true JP2008524218A5 (ru) 2012-03-08
JP5022911B2 JP5022911B2 (ja) 2012-09-12

Family

ID=36168678

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007546709A Expired - Fee Related JP5022911B2 (ja) 2004-12-17 2005-11-30 ゲムシタビンのアミドプロドラック、組成物、及びそれらの使用

Country Status (32)

Country Link
US (1) US7691827B2 (ru)
EP (1) EP1831237B1 (ru)
JP (1) JP5022911B2 (ru)
KR (1) KR100874052B1 (ru)
CN (1) CN101080417B (ru)
AR (1) AR055009A1 (ru)
AT (1) ATE405573T1 (ru)
AU (1) AU2005316922B2 (ru)
BR (1) BRPI0519117A2 (ru)
CA (1) CA2589850C (ru)
CY (1) CY1108447T1 (ru)
DE (1) DE602005009255D1 (ru)
DK (1) DK1831237T3 (ru)
EA (1) EA011868B1 (ru)
ES (1) ES2310860T3 (ru)
HK (1) HK1109903A1 (ru)
HR (1) HRP20080529T3 (ru)
IL (1) IL183666A (ru)
MA (1) MA29154B1 (ru)
MX (1) MX2007007228A (ru)
MY (1) MY143677A (ru)
NO (1) NO20073368L (ru)
NZ (1) NZ554732A (ru)
PE (1) PE20060771A1 (ru)
PL (1) PL1831237T3 (ru)
PT (1) PT1831237E (ru)
RS (1) RS50629B (ru)
SI (1) SI1831237T1 (ru)
TW (1) TWI326687B (ru)
UA (1) UA86119C2 (ru)
WO (1) WO2006065525A1 (ru)
ZA (1) ZA200705019B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101448504B (zh) * 2006-06-21 2012-04-11 伊莱利利公司 吉西他滨酰胺前体药物的结晶形式、其组合物以及用途
TWI436775B (zh) 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
CN101525361B (zh) 2009-04-21 2010-11-17 济南圣鲁金药物技术开发有限公司 基于吉西他滨结构的前药及其合成方法及应用
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
CN102432654A (zh) * 2011-09-26 2012-05-02 宋云龙 吉西他滨酰胺衍生物及其制备方法和用途
CA2890359A1 (en) 2012-11-07 2014-05-15 Zucai SUO Substituted gemcitabine aryl amide analogs and treatment methods using same
AU2013345007B2 (en) 2012-11-13 2018-08-30 BoYen Therapeutics, Inc. Gemcitabine prodrugs and uses thereof
US10059733B2 (en) 2014-03-03 2018-08-28 Nucorion Pharmaceuticals, Inc. Gemcitabine analogs
WO2016078160A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 胞苷衍生物及其应用
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
EP3746134A1 (en) 2018-02-02 2020-12-09 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
WO2019204869A1 (en) * 2018-04-26 2019-10-31 NanoMed Holdings Pty Ltd Gemcitabine amphiphile prodrugs
CN108864250A (zh) * 2018-05-29 2018-11-23 北京大学 一种FAPα酶敏感的吉西他滨前体药物及其制备方法和应用
SG11202100411TA (en) * 2018-08-03 2021-02-25 Cellix Bio Private Ltd Compositions and methods for the treatment of cancer
WO2021216427A1 (en) 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
YU43193A (sh) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
RU2131880C1 (ru) * 1992-06-22 1999-06-20 Эли Лилли Энд Компани Способ получения обогащенных бета-аномером нуклеозидов
ATE236188T1 (de) * 1997-01-24 2003-04-15 Conpharma As Gemcitabin-derivate
GB2321454A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Gemcitabine esters and amides
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6624142B2 (en) * 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6376470B1 (en) * 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
US7265096B2 (en) * 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US7846436B2 (en) * 2003-11-28 2010-12-07 Chemgenes Corporation Oligonucleotides and related compounds

Similar Documents

Publication Publication Date Title
JP2008524218A5 (ru)
CY1121330T1 (el) Συνθεσεις που περιλαμβανουν αζελαστινη και μεθοδοι χρησης αυτων
NO20092033L (no) Nye forbindelser
ES2360841T3 (es) Derivados de 1,3-dihidroimidazol-2-tiona como inhibidores de dopamina-beta-hidroxilasa.
JP2010514829A5 (ru)
NO20083059L (no) Pyrimidinderivater
JP2014511892A5 (ru)
CL2008001898A1 (es) Compuestos derivados de pirazinona, inhibidores de p38; proceso de preparacion de estos; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende; uso para tratar enferemedades pulmonares obstructivas cronicas y asma.
UY27627A1 (es) Aza - arilpiperazinas
JP2016510323A5 (ru)
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
CY1113269T1 (el) Παραγωγα ινδαζολυλ αμιδιου για τη θεραπευτικη αγωγη διαταραχων διαμεσολαβουμενων υπο υποδοχεα γλυκοκορτικοειδων
PA8534801A1 (es) Derivados de piperazina
JP2009502743A5 (ru)
JP2006509749A5 (ru)
CA2589850A1 (en) Amide prodrug of gemcitabine, compositions and use thereof
EA200971086A1 (ru) Фармацевтические композиции и способ лечения шизофрении
JP2014505107A5 (ru)
BRPI0706863A2 (pt) composição de fármacos, uso de uma composição de fármacos e embalagem comercial
CN104302624B (zh) 抗疟疾剂
ECSP099767A (es) Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas
JP2007534634A5 (ru)
JP2017522304A5 (ru)
JP2009508876A5 (ru)
JP2012508256A5 (ru)